#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Glycogen storage disease type II Marginal zone lymphoma refractory Ataxia telangiectasia Henoch-Schonlein purpura Mantle cell lymphoma stage IV Chronic cutaneous lupus erythematosus Neurofibromatosis Richter's syndrome Prolymphocytic leukaemia Gastrointestinal disorder Aspergillus infection Ventricular fibrillation Cholangiocarcinoma Pelizaeus-Merzbacher disease Cardiac sarcoidosis More trials…

    Learn about Rare Diseases

    Mantle cell lymphoma refractory – Treatment Aicardi-Goutieres syndrome – Trials in Disease Alagille syndrome – Trials in Disease X-linked lymphoproliferative syndrome – Treatment Toxic epidermal necrolysis – Treatment Mucopolysaccharidosis – Life with Disease SAPHO syndrome – Basic Information Hairy cell leukaemia recurrent – Treatment Retinitis pigmentosa – Basic Information Metachromatic leukodystrophy – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    ASP2957 ORX750 METHYLPHENIDATE Avalglucosidase Alfa Ciprofloxacin Hydrochloride POTASSIUM CLAVULANATE Atazanavir ACARBOSE Clobetasol Citicoline Sodium Cl-Ad-Msc-002 Burfiralimab CIRTUVIVINT Vibostolimab Mitapivat Flucloxacillin MOLNUPIRAVIR Tegafur Cerebrolysin Concentrate Gskvx000000008866 More therapies…

    Learn about Your Condition

    Hypervolaemia Haemolytic uraemic syndrome Peritoneal sarcoma Hypogonadism male Hepatobiliary cancer Endometrial cancer stage I Bladder cancer recurrent Hyperoxaluria Frostbite Primary hyperoxaluria Hypertrophic scar Solitary fibrous tumour Delirium Periodontitis Dry eye More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Study Comparing Ipilimumab and Nivolumab to Nivolumab Alone for Patients with Resectable Stage III Melanoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Malignant melanoma stage III
    Investigated Drugs:
    • Ipilimumab
    • Nivolumab
    Sweden

  • Study on Pain Relief and Safety of Low-Dose Intrathecal Morphine for Women Undergoing Planned Caesarean Section

    Recruiting

    3 1 1
    Investigated Diseases:
    • Caesarean section
    Investigated Drugs:
    • Morphine Hydrochloride
    Denmark

  • Study on the Safety of CNTY-101 and Aldesleukin for Patients with Active Autoimmune Diseases: Lupus, Scleroderma, and Myositis

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Idiopathic inflammatory myopathy
    • Systemic lupus erythematosus
    • Systemic scleroderma
    Investigated Drugs:
    • Aldesleukin
    Germany

  • Study on the Safety and Effectiveness of Emicizumab for Patients with Type 3 Von Willebrand Disease

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Von Willebrand’s disease
    Investigated Drugs:
    • Efmoroctocog Alfa
    • Eptacog Alfa (Activated)
    • Factor Viii Inhibitor Bypassing Fraction
    Belgium France Germany Italy The Netherlands Poland +2

  • Study on the Safety and Effectiveness of Cytisinicline for Helping Smokers Quit

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Cytisinicline
    Spain

  • Study of elranatamab and lenalidomide combination versus standard chemotherapy and transplant in newly diagnosed multiple myeloma patients

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Elranatamab
    • Bortezomib
    • Daratumumab
    France
Previous Page
1 … 217 218 219 220 221 … 1,648
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!